South Dakota Investment Council Has $2.04 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

South Dakota Investment Council lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,283 shares of the medical device company’s stock after purchasing an additional 4,400 shares during the quarter. South Dakota Investment Council’s holdings in DexCom were worth $2,044,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of DXCM. Blue Trust Inc. raised its position in shares of DexCom by 101.9% during the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after purchasing an additional 898 shares during the period. Private Advisor Group LLC raised its position in shares of DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock worth $759,000 after purchasing an additional 608 shares during the period. International Assets Investment Management LLC acquired a new position in shares of DexCom during the third quarter worth approximately $930,000. Hennion & Walsh Asset Management Inc. grew its holdings in DexCom by 15.1% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 4,409 shares of the medical device company’s stock worth $296,000 after buying an additional 579 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its holdings in DexCom by 0.5% during the third quarter. IFM Investors Pty Ltd now owns 80,794 shares of the medical device company’s stock worth $5,416,000 after buying an additional 415 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on DXCM. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.06.

DexCom Stock Down 0.6 %

Shares of NASDAQ DXCM opened at $88.78 on Monday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business’s fifty day moving average price is $83.50 and its 200-day moving average price is $76.06. The stock has a market capitalization of $34.69 billion, a PE ratio of 62.08, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,083 shares of company stock valued at $3,309,794. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.